Lowest-Effective-Dose GLP-1 Protocol
Match the smallest tolerated dose to a defined clinical goal
- Difficulty
- Expert
- Time to result
- ~ongoing to results
- Steps
- 6
- Confidence
- 94%
Dr. Tina Moore describes an individualized approach to GLP-1 treatment rather than automatic escalation to a standard high dose. The mechanism is goal-led titration: establish what improvement is being sought, begin at a clinician-selected low dose, monitor the response, and avoid pushing far enough to suppress appetite or create symptoms unnecessarily. Lifestyle support is part of the intervention, not an optional add-on, because strength training, protein intake, sleep, movement, and food quality help protect muscle and improve metabolic health. Moore also describes lengthening the interval or taking supervised breaks as patients improve, although she presents receptor resensitization and microdosing benefits as her clinical hypothesis and practice rather than settled long-term evidence. The protocol therefore depends on informed consent, medical oversight, and repeated reassessment.
Origin
Extracted from The Diary of a CEO
Core principles
- 01Use a defined short-term and long-term clinical goal
- 02Seek the lowest dose that produces a favourable response
- 03Keep the patient below unwanted symptoms rather than chasing a standard escalation
- 04Treat medication as one tool within a broader lifestyle plan
- 05Reassess spacing or cycling instead of assuming indefinite escalation
How to run it
- 1
Set the treatment target
A qualified clinician and patient define the short-term symptom or marker being addressed and the longer-term outcome. The transcript's examples include pain, skin lesions, blood pressure, and metabolic health, but it does not establish efficacy for each use.
Pro tip Write down the target before discussing dose changes.
Watch out Many uses discussed in the episode are off-label or supported mainly by the guest's clinical experience and should not be treated as established indications.
- 2
Establish a monitored baseline
Review current symptoms, health conditions, medications, nutrition, muscle-protection habits, and appropriate laboratory measures before treatment. This creates a comparison point for benefit and harm.
Pro tip Include mood and gastrointestinal function in the baseline rather than tracking weight alone.
Watch out Screening and prescribing decisions belong to a qualified medical professional.
- 3
Use the clinician-selected minimum
Moore advocates beginning below the dose that produces unwanted symptoms and not escalating automatically. The episode deliberately withholds a universal microdose because the amount depends on the patient.
Pro tip Judge the dose against the stated goal, not another patient's amount.
Watch out Do not infer or calculate a personal dose from this framework.
- 4
Build the lifestyle support
Add strength training, adequate protein, nutrient-dense food, regular walking, light exposure, sleep protection, and stress management as appropriate. Moore frames medication as one component of a multi-pronged plan.
Pro tip Protect muscle with resistance training and sufficient nutrition from the start.
Watch out Appetite suppression can reduce food intake enough to compromise nutrition and lean mass.
- 5
Monitor benefits and harms
Track the agreed outcome alongside nausea, vomiting, appetite loss, mood changes, gastrointestinal symptoms, and relevant laboratory results. Maintain close contact rather than issuing a prescription without follow-up.
Pro tip Use a simple weekly log so trends are visible at review.
Watch out Concerning or severe symptoms require prompt medical assessment, not dose experimentation.
- 6
Reassess dose and interval
If the patient improves, Moore tests whether the dose can remain stable or the interval can be lengthened under supervision. If symptoms or plateaus appear, reassess the whole plan rather than reflexively escalating.
Pro tip Ask which missing support or changed condition could explain a plateau.
Watch out The episode acknowledges that long-term clinical evidence for GLP-1 microdosing is not yet established.
In the wild
Moore says she began her older, medically complex mother on a very small amount of semaglutide because she was frail and already had gastrointestinal problems. After her mother increased the amount herself and developed symptoms, Moore reduced it again and continued weekly monitoring while exploring how long she could go between doses. This is a personal case report from the guest, not controlled evidence.
→ Moore reports improved joint pain, gut function, cognition, and anxiety, while acknowledging continued medication and monitoring.
Illustrative example: a screened patient and prescriber agree that the target is improved blood pressure without appetite loss. They record a baseline, use the prescriber's selected dose, add resistance exercise and adequate protein, and review symptoms and measurements regularly. If nausea appears, the patient contacts the clinician rather than changing the dose alone.
→ The treatment decision remains tied to a measurable goal and tolerability rather than a fixed escalation calendar.
Common mistakes
Treating microdosing as self-help
The guest explicitly discourages buying semaglutide online and adjusting it at home. The approach she describes requires prescribing, screening, and monitoring.
Escalating because the calendar says so
Automatic escalation can ignore a patient's response and side effects. Moore argues that the clinical goal and tolerability should drive reassessment.
Using medication without support
Suppressing appetite while keeping the same low-quality diet and avoiding resistance training can undermine nutrition and muscle protection.
Is it for you?
Best for
It is best for qualified clinicians and appropriately screened patients considering individualized GLP-1 treatment with close follow-up.
Not ideal for
It is not appropriate for self-prescribing, unsupervised dose changes, or anyone seeking a transcript-derived dosing instruction.
From the transcript
“my goal is always just to dose people just below symptoms”
“I don't ever do semaglutide as a monotherapy.”
“It's close monitoring. You're making sure to keep track of things.”
From the episode
The Ozempic Expert: Ozempic Transforms Your Gut Microbiome! People Are Being Overdosed On Ozempic! Microdosing Saved My Life! - Dr Tyna Moore